TY - JOUR
T1 - Near-infrared raman microspectroscopy detects high-risk human papillomaviruses1
AU - Vargis, Elizabeth
AU - Tang, Yi Wei
AU - Khabele, Dineo
AU - Mahadevan-Jansen, Anita
N1 - Funding Information:
Address all correspondence to: Anita Mahadevan-Jansen, PhD, VU Station B Box 351631, Nashville, TN 37235. E-mail: [email protected] 1The authors acknowledge the financial support of the National Institutes of Health (grant no. R01-CA-095405), a predoctoral fellowship (grant no. T32-HL7751-15), and the Lai Sulin Scholarship for E.V. The authors have no commercial affiliations or financial interests that would be considered conflicts of interest. 2Current address: Center for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37831. 3Current address: Department of Laboratory Medicine, Memorial Sloan‐Kettering Cancer Center, New York, NY 10065. Received 30 January 2012; Revised 30 January 2012; Accepted 1 March 2012 Copyright © 2012 Neoplasia Press, Inc. Open access under CC BY-NC-ND license. 1944-7124/12 DOI 10.1593/tlo.12106
PY - 2012/6
Y1 - 2012/6
N2 - BACKGROUND: Detecting human papillomaviruses (HPVs) infection in cervical cells is an exceedingly important part of the clinical management of cervical dysplasia. Current guidelines in women's health outline the need for both the Papanicolaou test as well as high-risk HPV testing. Testing for HPV is expensive, is time-consuming, and requires experienced technicians. METHODS: Two sets of near-infrared Raman microspectroscopy experiments were conducted using a Raman confocal microscope system. First, Raman spectra were acquired from four different cell culture lines, two positive for HPV (HeLa, SiHa), one negative for HPV, but malignant (C33A), and one normal, HPV-negative line (NHEK). The three malignant lines were all derived from cervical cells. Second, Raman spectra were acquired from deidentified patient samples that were previously tested for the presence of high-risk HPV. RESULTS: The spectra from the cell culture lines and the patient samples contained many statistically significant differences. Using sparse multinomial logistic regression to classify the data led to classification accuracies of 89% to 97% for the cell culture samples and 98.5% for the patient samples. CONCLUSIONS: Raman microspectroscopy can be used to detect HPV and differentiate among specific HPV strains. This technique may provide health providers with a new method for quickly testing cell samples for the presence of HPV.
AB - BACKGROUND: Detecting human papillomaviruses (HPVs) infection in cervical cells is an exceedingly important part of the clinical management of cervical dysplasia. Current guidelines in women's health outline the need for both the Papanicolaou test as well as high-risk HPV testing. Testing for HPV is expensive, is time-consuming, and requires experienced technicians. METHODS: Two sets of near-infrared Raman microspectroscopy experiments were conducted using a Raman confocal microscope system. First, Raman spectra were acquired from four different cell culture lines, two positive for HPV (HeLa, SiHa), one negative for HPV, but malignant (C33A), and one normal, HPV-negative line (NHEK). The three malignant lines were all derived from cervical cells. Second, Raman spectra were acquired from deidentified patient samples that were previously tested for the presence of high-risk HPV. RESULTS: The spectra from the cell culture lines and the patient samples contained many statistically significant differences. Using sparse multinomial logistic regression to classify the data led to classification accuracies of 89% to 97% for the cell culture samples and 98.5% for the patient samples. CONCLUSIONS: Raman microspectroscopy can be used to detect HPV and differentiate among specific HPV strains. This technique may provide health providers with a new method for quickly testing cell samples for the presence of HPV.
UR - https://www.scopus.com/pages/publications/84862027121
U2 - 10.1593/tlo.12106
DO - 10.1593/tlo.12106
M3 - Article
AN - SCOPUS:84862027121
SN - 1936-5233
VL - 5
SP - 172
EP - 179
JO - Translational Oncology
JF - Translational Oncology
IS - 3
ER -